Etoposide attenuates zymosan-induced shock in mice

Inflammation

Volumn 31, Issue 1, 2008, Pages 57-64

  Remichkova, M ^a   Yordanov, M ^a   Dimitrova, P ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Etoposide; Macrophages; Zymosan induced shock

Indexed keywords

ETOPOSIDE; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; LUNG ALVEOLUS MACROPHAGE; MORTALITY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SCID MOUSE; SHOCK; SURVIVAL RATE; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; INFLAMMATION; LIVER; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, SCID; ORGAN SIZE; SEPSIS; SHOCK; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

MUS;

EID: 39049113341     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-007-9049-8     Document Type: Article

References (27)

1. Deitch, E. A. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11.
2. Carpati, C. M., M. E. Astiz, and E. C. Rackow. 1999. Mechanisms and management of myocardial dysfunction in septic shock. Crit. Care. Med. 27:231-232.
3. Karima, R., S. Matsumoto, H. Higashi, and K. Matsushima. 1999. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5:123-132.
4. Davies, M. G., and P. O. Hagen. 1997. Systemic inflammatory response syndrome. Br. J. Surg. 84:920-935.
5. Nelson, S. 1999. A question of balance. Am. J. Respir. Crit. Care Med. 159:1365-1367.
6. Goris, R. J., W. K. Boekholtz, I. P. van Bebber, J. K. Nuytinck, and P. H. Schillings. 1986. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch. Surg. 121:897-901.
7. Underhill, D. M. 2003. Macrophage recognition of zymosan particles. J. Endotoxin. Res. 9:176-180.
8. Meng, G., A. Grabiec, M. Rutz, J. Metzger, P. B. Luppa, H. Wagner, S. Bauer, and C. J. Kirschning. 2005. Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol. Lett. 98:200-207.
9. Sfeir, T., D. C. Saha, M. Astiz, and E. C. Rackow. 2001. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit. Care Med. 29:129-133.
10. von Asmuth, E. J., J. G. Maessen, C. J. van der Linden, and W. A. Buurman. 1990. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand. J. Immunol. 32:313-319.
11. Aldridge, A. J. 2002. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur. J. Surg. 168:204-214.
12. Baker, C. C., and M. D. Huynh. 1995. Sepsis in the critically ill patient. Curr. Probl. Surg. 32:1013-1083.
13. Aisner, J., and E. J. Lee. 1991. Etoposide. Current and future status. Cancer 67:215-219.
14. Hande, K. R. 1998. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34:1514-1521.
15. Johnson, D. H., J. D. Hainsworth, K. R. Hande, and F. A. Greco. 1991. Current status of etoposide in the management of small cell lung cancer. Cancer 67:231-244.
16. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7:625-655.
17. Blackwell, T. S., and J. W. Christman. 1996. Sepsis and cytokines: current status. Br. J. Anaesth. 77:110-117.
18. Burdon, D., T. Tiedje, K. Pfeffer, E. Vollmer, and P. Zabel. 2000. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit. Care Med. 28:1962-1967.
19. Calame, W., A. E. Douwes-Idema, M. T. van den Barselaar, R. van Furth, and H. Mattie. 1994. Influence of cytostatic agents on the pulmonary defence of mice infected with Klebsiella pneumoniae and on the efficacy of treatment with ceftriaxone. J. Infect. 29:53-66.
20. Calame, W., R. van der Waals, H. Mattie, and R. van Furth. 1989. Influence of etoposide and cyclophosphamide on the efficacy of cloxacillin and erythromycin in an experimental staphylococcal infection. Antimicrob. Agents Chemother. 33:980-982.
21. Verdrengh, M., O. Isaksson, and A. Tarkowski. 2005. Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis. Rheumatology (Oxford) 44:183-186.
22. Verdrengh, M., and A. Tarkowski. 2003. Impact of topoisomerase II inhibition on cytokine and chemokine production. Inflamm. Res. 52:148-153.
23. Nieuwenhuijzen, G. A., M. F. Knapen, T. Hendriks, N. van Rooijen, and R. J. Goris. 1997. Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice. Arch. Surg. 132:533-539.
24. Jansen, M. J., T. Hendriks, M. T. Vogels, J. W. van der Meer, and R. J. Goris. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit. Care Med. 24:1196-1202.
25. Volman, T. J., R. J. Goris, M. van der Jagt, F. A. van de Loo, and T. Hendriks. 2002. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit. Care Med. 30:1553-1559.
26. Seiter, K. 2005. Toxicity of the topoisomerase II inhibitors. Expert. Opin. Drug Saf. 4:219-234.
27. Goldmann, O., G. S. Chhatwal, E. Medina. 2005. Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J. Infect. Dis. 191:1280-1286.